News stories about Recro Pharma (NASDAQ:REPH) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a news impact score of 0.16 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.1239881216267 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Recro Pharma (NASDAQ REPH) traded up $0.15 during trading on Friday, hitting $8.87. 74,262 shares of the company’s stock traded hands, compared to its average volume of 104,004. Recro Pharma has a one year low of $5.81 and a one year high of $10.59. The firm has a market cap of $166.79, a PE ratio of -4.05 and a beta of -0.50. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35.
A number of equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Recro Pharma presently has a consensus rating of “Hold” and an average target price of $11.65.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The stock was sold at an average price of $9.56, for a total transaction of $126,086.84. Following the sale, the insider now directly owns 2,243,064 shares in the company, valued at $21,443,691.84. The disclosure for this sale can be found here. Insiders have sold a total of 860,414 shares of company stock worth $8,289,916 over the last ninety days. 21.60% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Recro Pharma (REPH) Given Daily Coverage Optimism Score of 0.16” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/13/recro-pharma-reph-given-daily-coverage-optimism-score-of-0-16.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.